Profile
Sector:
HealthcareIndustry:
Medical DevicesCountry:
United KingdomIPO:
16 November 1999Website:
http://www.smith-nephew.comNext earnings report:
27 February 2025Last dividends:
04 October 2024Next dividends:
N/APrice
after hours | Fri, 01 Nov 2024 21:05:00 GMTAnalysts recommendations
Institutional Ownership
SNN Latest News
Smith & Nephew plc (NYSE:SNN ) Q3 2024 Earnings Conference Call October 31, 2024 4:30 AM ET Company Participants Deepak Nath - CEO & Director John Rogers - CFO & Executive Director Conference Call Participants Jack Reynolds-Clark - RBC Capital Management David Adlington - J.P. Morgan Hassan Al-Wakeel - Barclays Robert Davies - Morgan Stanley Richard Felton - Goldman Sachs Graham Doyle - UBS Lisa Clive - Bernstein Julien Dormois - Jefferies Deepak Nath Good morning, and welcome to the Smith & Nephew third quarter trading update.
British medical equipment maker Smith & Nephew cut its annual underlying revenue growth forecast on Thursday to 4.5% from the previous outlook range of 5% to 6%, primarily hurt by challenges in its surgical businesses in China.
Smith & Nephew and JointVue announce a co-marketing agreement for the latter's OrthoSonic 3D Surgery Planning Technology.
Smith & Nephew introduces the LEGION Hinged Knee System with OXINIUM Technology, elevating knee revision surgery through innovation.
Patented technology further personalizes total knee arthroplasty for surgeons and patients Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces it has signed a co-marketing agreement with JointVue for its patented OrthoSonic™ 3D Surgery Planning Technology – the only ultrasound device currently on the market to deliver 3D preoperative planning. JointVue's technology allows surgeons using Smith+Nephew's CORI◊ Surgical System for robotic-assisted knee arthroplasty to create a personalized surgical plan, which may provide opportunities to improve patient satisfaction and operating room efficiency.
Smith & Nephew announces the completion of the first case using the CATALYSTEM Primary Hip System.
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces promising surgeon feedback from the first completed cases utilizing its new CATALYSTEM Primary Hip System. Designed to address the evolving demands of primary hip surgery - including the increased adoption of anterior approach procedures – the CATALYSTEM Primary Hip System features a triple-taper stem design with uniform proximal loading.1 The reduced distal stem geometry and shorter lengths are ideal for anterior approach but suitable for all approaches.2
Smith & Nephew announces the launch of its TOTAL ANKLE Patient-Matched Guides to plan and perform total ankle replacement procedures.
Smith & Nephew (SNN) inks a three-year agreement with InfuSystem (INFU) to distribute its RENASYS EDGE negative pressure wound therapy system.
Smith & Nephew (SNN) announces a collaboration with HOPCo to focus on enhancing solutions for ASC customers, physicians, and patients through the latter's digital health and analytics platforms.
What type of business is Smith & Nephew?
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products. It also provides sports medicine joint repair products comprise instruments, technologies, and implants to perform minimally invasive surgery, as well as treating soft tissue injuries and degenerative conditions of the shoulder, knee, hip, and small joints. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, high-definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg wounds, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, such as biologics and other bioactive technologies for debridement and dermal repair/regeneration, and regenerative medicine products, including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. The company serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.
What sector is Smith & Nephew in?
Smith & Nephew is in the Healthcare sector
What industry is Smith & Nephew in?
Smith & Nephew is in the Medical Devices industry
What country is Smith & Nephew from?
Smith & Nephew is headquartered in United Kingdom
When did Smith & Nephew go public?
Smith & Nephew initial public offering (IPO) was on 16 November 1999
What is Smith & Nephew website?
https://www.smith-nephew.com
Is Smith & Nephew in the S&P 500?
No, Smith & Nephew is not included in the S&P 500 index
Is Smith & Nephew in the NASDAQ 100?
No, Smith & Nephew is not included in the NASDAQ 100 index
Is Smith & Nephew in the Dow Jones?
No, Smith & Nephew is not included in the Dow Jones index
When was Smith & Nephew the previous earnings report?
No data
When does Smith & Nephew earnings report?
The next expected earnings date for Smith & Nephew is 27 February 2025